Assessment of the Prevalence of Hepatitis C and B Viruses in Patients with Hemophilia in Qom Province, (Iran)

Abstract

Background and Objectives: Hemophilia is a hereditary bleeding disorder, which CFC (clotting factor concentration) method is used for prevention and treatment of about 70% of these patients. This method can play an important role in the transmission of blood-borne viruses, such as hepatitis B and C. According to studies, more than 40% of patients with hemophilia have one of the hepatitis C, B, and D, or HIV. The objective of this study was to determine prevalence of hepatitis B and C in the hemophilia population of Qom province. Methods: This analytical cross-sectional study, was carried out on 90 patients with hemophilia Qom province, in 2017. Primary diagnosis and screening of hepatitis, were performed using serology for HBV and HCV; then, the samples were analyzed by PCR method. The data were statistically analyzed by Chi-square test. Results: In this study, 70 subjects of the statistical population were male and 20 subjects were female, and their mean age was 27 years. In the serological survey, anti HCV, HBsAg, and HBcAb, were positive in 27.8%, 0%, and 11.1%, respectively. Moreover, the results of the PCR test for HBV was negative and for HCV was positive in 9 out of 25 individuals, who were anti-HCV positive. Conclusion: The results of this study showed that among the bloodborne viral hepatitis in the hemophilia population, the incidence of hepatitis C is higher. Also, in recent years, monitoring the donated blood reduced the risk of the incidence of viral hepatitis in the blood recipient hemophilic populations. Accordingly, continuous testing and paying attention to the vaccination schedule seems to be necessary in this group of patients.

Perioperative Outcomes of Patients with Bleeding Disorders Undergoing Major Surgery at an Academic Hemophilia Treatment Center

“…Among hemophilia patients undergoing total joint arthroplasty, bleeding has been reported in 8.7% to 8.9% of cases. 20,21 In our study, four hemophilia patients (all with mild hemophilia A) underwent native total joint arthroplasty (three knee, one hip) with no bleeding events. One patient with mild hemophilia A underwent revision of a prior hip arthroplasty and had a major bleeding complication, with unexpected bleeding and ≥2 g/dL Hgb drop.…”

“… 18 , 19 Others have examined outcomes in patients with hemophilia undergoing orthopedic surgery, as chronic hemarthopathy often necessitates eventual arthroplasty in these patients. Bleeding complications occur in approximately 9% of these patients, 20 , 21 and infection and re-operation are also common complications. 21 – 23 However, data on PwBD undergoing other major surgeries 24 in the modern factor replacement era is scant, with one study finding excellent outcomes of patients undergoing abdominal surgeries at a hemophilia treatment center (HTC) 25 and another showing a bleeding complication rate of 3.4% among VWD patients undergoing both minor and major surgeries who received perioperative VWF-FVIII concentrate.…”